Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.

@article{Clavio2005IfosfamideEE,
  title={Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.},
  author={Marino Clavio and Alberto Garrone and Ivana Pierri and Gian Luca Michelis and M. Balocco and Alessandra Albarello and Riccardo Varaldo and Paolo Canepa and Maurizio Miglino and Filippo Ballerini and Letizia Canepa and Marco Gobbi},
  journal={Oncology reports},
  year={2005},
  volume={14 4},
  pages={933-40}
}
The IEV schedule consisted of epirubicin 100 mg/m2 on day 1, etoposide 150 mg/m2 on days 1-3, and ifosfamide 2.5 g/m2 on days 1-3. Patients who proceeded to haematopoietic stem cell transplants (HDTs) received conditioning therapy with BEAM [for the Hodgkin's Lymphoma (HL) and non-Hodgkin's Lymphoma (NHL) groups], or melphalan 100 mg/m2 and mitoxantrone… CONTINUE READING